2017 American Transplant Congress
Integration of Kidney-Exchange, (Un)Specified Living Donor Transplantation, ABO Incompatible and Desensitisation Programs in a Computerized Allocation Program: A Simulation.
Introduction: Our national kidney-exchange allocation program is established in 2004. Though kidney-exchange is intertwined with (un)specified donation and domino-paired procedures, the latter still operates by…2017 American Transplant Congress
A Phase Ib, Open Label, Single Arm Study to Assess the Safety, Pharmacokinetics, and Impact on Humoral Sensitization of SANGUINATE Infusion in Patients with End-Stage Renal Disease.
1U.Cincinnati, OH; 2Prolong Pharmaceuticals, NJ
Purpose:The endeavor and resources spent to study desensitization haven't been matched by an effort to investigate strategies to prevent sensitization.The purpose of this study was…2017 American Transplant Congress
Continuation of Immunosuppression Appears to Protect Against Allosensitization in Patients Listed for a Second Kidney Transplant.
Purpose: The current standard of practice after allograft loss is to discontinue immunosuppression (IS) to decrease complications related to prolonged exposure. There is a paucity…2017 American Transplant Congress
Course of Donor Specific Anti-HLA Antibodies After Induction Therapy with Rituximab in Renal Transplantation.
The presence of pre-existing or de novo donor-specific antibodies against HLA (DSA), is associated with a worse graft outcome after renal transplantation. B-cell depletion protocols…2017 American Transplant Congress
Dual Targeting with Carfilzomib and Tocilizumab Abrogates Antibody-Mediated Rejection and Prolongs Survival in a Highly Sensitized Rhesus Model of Kidney Transplantation.
Duke University Medical Center, Durham, NC; Cedars-Sinai Medical Center, Los Angeles, CA
Purpose:Sensitized recipients have poor access to kidney transplantation (KT) and worse outcomes when transplanted. We have shown that bortezomib inhibits plasma cells (PCs), but does…2017 American Transplant Congress
Long-Term Persistence of Anti-HLA Antibodies in Renal Trasplant Recipients: Risk Factors and Impact on Clinical Course.
Objectives:1) To evaluate the incidence of development of anti-HLA antibodies on the long run in our renal transplant population and the main risk factors for…2017 American Transplant Congress
De Novo Donor-Specific Antibodies After Allograft Nephrectomy.
Introduction: although the development of donor-specific antibodies (DSAs) is a known event after allograft nephrectomy (Nx), there are few studies describing the tempo, class and…2017 American Transplant Congress
Prevention of Donor Specific Antibody Production After Skin Allografting by Mobilization of Endogenous Stem Cells Using a Combination of AMD3100 and Low-Dose FK506 in Rats.
Background: We have developed a stem cell mobilizing strategy that enables long-term liver and kidney allograft survival without sustained immunosuppression in small and large animals…2017 American Transplant Congress
Significant Allosensitisation Despite Early, within 24 Hour, Graft Nephrectomy.
Introduction: Although it is well known that allograft nephrectomy (Nx) is followed by the development of donor-specific antibodies (DSAs) even after a short transplant period,…2017 American Transplant Congress
HLA Alloimmunization According to the Different Immunization Events and Consequences on Access to Kidney Transplantation.
Patients awaiting solid organ transplantation may develop anti-HLA antibodies after sensitization events such as transfusions, pregnancies or previous transplantations. The aim of our work was…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 19
- Next Page »